Search by Drug Name or NDC

    NDC 45737-0230-01 Bio-S-Pres 5; 50; 2.5 mg/mL; mg/mL; mg/mL Details

    Bio-S-Pres 5; 50; 2.5 mg/mL; mg/mL; mg/mL

    Bio-S-Pres is a ORAL SOLUTION/ DROPS in the HUMAN OTC DRUG category. It is labeled and distributed by Advanced Generic Corporation. The primary component is DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE.

    Product Information

    NDC 45737-0230
    Product ID 45737-230_b4c750b5-60bd-4135-a52f-529f315f3847
    Associated GPIs
    GCN Sequence Number 040290
    GCN Sequence Number Description guaifen/dextromethorphan/PE DROPS 50-5-2.5/1 ORAL
    HIC3 B4R
    HIC3 Description NON-OPIOID ANTITUSSIVE-DECONGESTANT-EXPECTORANT
    GCN 53092
    HICL Sequence Number 000216
    HICL Sequence Number Description GUAIFENESIN/DEXTROMETHORPHAN HBR/PHENYLEPHRINE
    Brand/Generic Generic
    Proprietary Name Bio-S-Pres
    Proprietary Name Suffix DX
    Non-Proprietary Name Dextromethorphan HBr, Guaifenesin, Phenylephrine HCl
    Product Type HUMAN OTC DRUG
    Dosage Form SOLUTION/ DROPS
    Route ORAL
    Active Ingredient Strength 5; 50; 2.5
    Active Ingredient Units mg/mL; mg/mL; mg/mL
    Substance Name DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE
    Labeler Name Advanced Generic Corporation
    Pharmaceutical Class Adrenergic alpha1-Agonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]
    DEA Schedule n/a
    Marketing Category OTC MONOGRAPH FINAL
    Application Number part341
    Listing Certified Through 2024-12-31

    Package

    NDC 45737-0230-01 (45737023001)

    NDC Package Code 45737-230-01
    Billing NDC 45737023001
    Package 30 mL in 1 BOTTLE (45737-230-01)
    Marketing Start Date 2013-03-01
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL b3b9c298-4524-4ba7-a831-3bf3c2950e27 Details

    Revised: 12/2020